Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Triamcinolone acetonide as an adjunct to bevacizumab for prevention of corneal neovascularization in a rat model
by
Mehrjardi, Hadi Z
, Mahbod, Mirgholamreza
, Hashemi, Hassan
, Ghaffari, Reza
in
Corneal Neovascularization; Triamcinolone Acetonide; Subconjunctival Bevacizumab Adjunctive Therapy; Neovascularization Inhibition
/ Dosage and administration
/ Neovascularization
/ Original
/ Prevention
/ Triamcinolone
2014
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Triamcinolone acetonide as an adjunct to bevacizumab for prevention of corneal neovascularization in a rat model
by
Mehrjardi, Hadi Z
, Mahbod, Mirgholamreza
, Hashemi, Hassan
, Ghaffari, Reza
in
Corneal Neovascularization; Triamcinolone Acetonide; Subconjunctival Bevacizumab Adjunctive Therapy; Neovascularization Inhibition
/ Dosage and administration
/ Neovascularization
/ Original
/ Prevention
/ Triamcinolone
2014
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Triamcinolone acetonide as an adjunct to bevacizumab for prevention of corneal neovascularization in a rat model
by
Mehrjardi, Hadi Z
, Mahbod, Mirgholamreza
, Hashemi, Hassan
, Ghaffari, Reza
in
Corneal Neovascularization; Triamcinolone Acetonide; Subconjunctival Bevacizumab Adjunctive Therapy; Neovascularization Inhibition
/ Dosage and administration
/ Neovascularization
/ Original
/ Prevention
/ Triamcinolone
2014
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Triamcinolone acetonide as an adjunct to bevacizumab for prevention of corneal neovascularization in a rat model
Journal Article
Triamcinolone acetonide as an adjunct to bevacizumab for prevention of corneal neovascularization in a rat model
2014
Request Book From Autostore
and Choose the Collection Method
Overview
To evaluate the short-term effects of a single subconjunctival injection of triamcinolone acetonide as an adjunct to subconjunctival bevacizumab for prevention of corneal neovascularization in rats.
Chemical cauterization was performed in the central cornea of the right eye in 48 male Sprague-Dawley rats (4 eyes were excluded due to perforation and/or infection). Immediately after the injury, the rats were randomly assigned to four treatment groups: controls (n=10), received subconjunctival injection of 0.02 mL balanced salt solution; group 1 (n=12), received 0.02 mL bevacizumab (25 mg/mL); group 2 (n=11), were treated with 0.02 mL triamcinolone acetonide (40 mg/mL); and group 3 (n=11), received both bevacizumab and triamcinolone acetonide. On days 7 and 14 after cauterization, digital photographs of the corneas were taken and the area of neovascularization was calculated and compared among the study groups.
The area of corneal neovascularization in all three treatment groups was less than the controls (P<0.05 for all comparisons). On day 7, the corneal avascular area was largest in group 3 (63%). On day 14, the area of corneal neovascularization in groups 2 and 3 was smaller than that in group 1 (P=0.031 and 0.011, respectively), but the difference between groups 2 and 3 was not statistically significant (P=0.552). Microscopic evaluation of the cornea was compatible with gross findings; inflammation and the number of new vessels was the least in group 3.
Triamcinolone acetonide was more effective than bevacizumab in inhibiting corneal neovascularization. Its adjunctive administration to bevacizumab resulted in even better prevention of corneal neovascularization. However, the produced combined effect was less than the sum of their separate effects and did not match additive or synergistic interactions.
Publisher
Medknow Publications and Media Pvt. Ltd,Knowledge E,Ophthalmic Research Center
This website uses cookies to ensure you get the best experience on our website.